Direct intranodal lymphangiography for recurrent chylous ascites following liver‐kidney transplantation
Aaron M. Williams, Thomas M. Seay, Jonathan C. Hundley, Roberto Gedaly – 25 June 2014
Recurrent or de novo nonalcoholic fatty liver disease after liver transplantation: Natural history based on liver biopsy analysis
Mélanie Vallin, Olivier Guillaud, Olivier Boillot, Valérie Hervieu, Jean‐Yves Scoazec, Jérôme Dumortier – 25 June 2014 – Nonalcoholic fatty liver disease (NAFLD) is a potential long‐term complication after liver transplantation (LT) and can occur as recurrent disease in patients undergoing transplantation for NAFLD or as de novo NAFLD in others. The aim of this study was to compare these 2 different entities.
Management of disordered hemostasis and coagulation in patients with cirrhosis
Nicolas M. Intagliata, Stephen H. Caldwell – 25 June 2014 – Watch a video presentation of this article
New all‐oral HCV therapies for genotype 1: A final good‐bye to interferon
Anna S.F. Lok – 25 June 2014 – Watch a video presentation of this article
Management of disordered hemostasis and coagulation in patients with cirrhosis
Nicolas M. Intagliata, Stephen H. Caldwell – 25 June 2014 – Watch a video presentation of this article
Benign and malignant hepatocellular lesions in patients with vascular liver disease
Valérie Vilgrain, Pierre‐Emmanuel Rautou, Valérie Paradis, Maxime Ronot – 25 June 2014 – Watch a video presentation of this article
Frequent incidence of escape mutants after successful hepatitis B vaccine response and stopping of nucleos(t)ide analogues in liver transplant recipients
Masatoshi Ishigami, Takashi Honda, Yoji Ishizu, Yasuharu Onishi, Hideya Kamei, Kazuhiko Hayashi, Yasuhiro Ogura, Yoshiki Hirooka, Hidemi Goto – 25 June 2014 – The combination of nucleos(t)ide analogues (NAs) and hepatitis B immune globulin has been established as safe and effective prophylaxis against hepatitis B virus (HBV) reactivation after liver transplantation (LT). However, the essential weak point of this regimen is its high cost.
A cell‐surface β‐hydroxylase is a biomarker and therapeutic target for hepatocellular carcinoma
Arihiro Aihara, Chiung‐Kuei Huang, Mark J. Olsen, Qiushi Lin, Waihong Chung, Qi Tang, Xiaoqun Dong, Jack R. Wands – 20 June 2014 – Hepatocellular carcinoma (HCC) has a poor prognosis as a result of widespread intra‐ and extrahepatic metastases. There is an urgent need to understand signaling cascades that promote disease progression. Aspartyl‐(asparaginyl)‐β‐hydroxylase (ASPH) is a cell‐surface enzyme that generates enhanced cell motility, migration, invasion, and metastatic spread in HCC. We hypothesize that inhibition of its enzymatic activity could have antitumor effects.
Standing the test of time: Outcomes of a decade of prioritizing patients with hepatocellular carcinoma, results of the UNOS natural geographic experiment
Karim J. Halazun, Rachel E. Patzer, Abbas A. Rana, Elizabeth C. Verna, Adam D. Griesemer, Ronald F. Parsons, Benjamin Samstein, James V. Guarrera, Tomoaki Kato, Robert S. Brown, Jean C. Emond – 20 June 2014
Reduced expression of transcriptional intermediary factor 1 gamma promotes metastasis and indicates poor prognosis of hepatocellular carcinoma
Ze‐yang Ding, Guan‐nan Jin, Wei Wang, Wei‐xun Chen, Yan‐hui Wu, Xi Ai, Lin Chen, Wan‐guang Zhang, Hui‐fang Liang, Arian Laurence, Ming‐zhi Zhang, Pran K. Datta, Bixiang Zhang, Xiao‐ping Chen – 20 June 2014 – Transcriptional intermediary factor 1 gamma (TIF1γ) may play either a potential tumor‐suppressor or ‐promoter role in cancer. Here we report on a critical role of TIF1γ in the progression of hepatocellular carcinoma (HCC). Reduced expression of TIF1γ was detected in HCC, especially in advanced HCC tissues, compared to adjacent noncancerous tissues.